NanoRepro AG (NN6) - Total Liabilities

Latest as of December 2025: €678.46K EUR ≈ $793.19K USD

Based on the latest financial reports, NanoRepro AG (NN6) has total liabilities worth €678.46K EUR (≈ $793.19K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NanoRepro AG strategic investment ratio to see how much of total assets are deployed in long-term investments.

NanoRepro AG - Total Liabilities Trend (2008–2025)

This chart illustrates how NanoRepro AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NanoRepro AG balance sheet assets.

NanoRepro AG Competitors by Total Liabilities

The table below lists competitors of NanoRepro AG ranked by their total liabilities.

Company Country Total Liabilities
Agroton Public Ltd.
WAR:AGT
Poland zł2.76 Million
Interhides Public Company Limited
BK:IHL
Thailand ฿2.50 Billion
Vietnam Petroleum Transport JSC
VN:VIP
Vietnam ₫128.89 Billion
Key Tronic Corporation
NASDAQ:KTCC
USA $219.78 Million
Geomega Resources Inc
V:GMA
Canada CA$5.97 Million
GEE Group Inc
NYSE MKT:JOB
USA $8.97 Million
A SPAC III Acquisition Corp. Class A Ordinary Shares
NASDAQ:ASPC
USA $535.96K
Seoyon Topmetal Co. Ltd
KQ:019770
Korea ₩82.46 Billion

Liability Composition Analysis (2008–2025)

This chart breaks down NanoRepro AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NanoRepro AG net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 36.72 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.02 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.02 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NanoRepro AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NanoRepro AG (2008–2025)

The table below shows the annual total liabilities of NanoRepro AG from 2008 to 2025.

Year Total Liabilities Change
2025-12-31 €678.46K
≈ $793.19K
-23.25%
2024-12-31 €884.03K
≈ $1.03 Million
-18.30%
2023-12-31 €1.08 Million
≈ $1.27 Million
-47.01%
2022-12-31 €2.04 Million
≈ $2.39 Million
-90.52%
2021-12-31 €21.54 Million
≈ $25.18 Million
+577.36%
2020-12-31 €3.18 Million
≈ $3.72 Million
+749.78%
2019-12-31 €374.21K
≈ $437.49K
+98.93%
2018-12-31 €188.12K
≈ $219.93K
-49.61%
2017-12-31 €373.31K
≈ $436.44K
-22.03%
2016-12-31 €478.78K
≈ $559.74K
+190.84%
2015-12-31 €164.62K
≈ $192.46K
-37.88%
2014-12-31 €265.00K
≈ $309.81K
+88.29%
2013-12-31 €140.74K
≈ $164.54K
-29.07%
2012-12-31 €198.42K
≈ $231.97K
+41.75%
2011-12-31 €139.97K
≈ $163.65K
-62.53%
2010-12-31 €373.59K
≈ $436.76K
+51.56%
2009-12-31 €246.49K
≈ $288.18K
+25.89%
2008-12-31 €195.80K
≈ $228.91K
--

About NanoRepro AG

XETRA:NN6 Germany Diagnostics & Research
Market Cap
$25.29 Million
€21.63 Million EUR
Market Cap Rank
#24435 Global
#2103 in Germany
Share Price
€1.72
Change (1 day)
+0.88%
52-Week Range
€1.38 - €2.29
All Time High
€17.14
About

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preve… Read more